Change at the helm of Poxel: Laure-Hélène Mercier appointed President

Poxel, a biopharmaceutical company specializing in treatments for chronic diseases, announces the appointment of Laure-Hélène Mercier as Chair of its Board of Directors. She succeeds Sophie Jacq Lapointe, effective September 3, 2026. This change aims to strengthen governance and dialogue with shareholders. The appointment is still subject to ratification at the next Annual General Meeting.

Laure-Hélène Mercier has over twenty years of experience in the biotechnology industry and finance. Her appointment comes at a time of opportunity for Poxel, which hopes to enhance the value of its clinical assets through rigorous financial management and increased transparency.